Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mitsubishi’s Oral Radicava Provides Convenience Option For ALS

May 13 2022

• By Joseph Haas

magnetic resonance image (MRI) of the brain human — Oral formulation may make Mitsubishi's ALD drug easier to administer

Related Content

Emmaus and Mitsubishi Tanabe Refuse To Take EU Approval Blows Quietly

May 30 2019

AstraZeneca's Ultomiris Disappoints In ALS, Setting Back Rare Disease Ambitions

Aug 20 2021

Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim

Jan 17 2022

Tale Of Two ALS Drugs: Similar Study Design, Different Take By US FDA

Mar 31 2022

Amylyx’s ALS Drug Should Wait For Phase III Results, US FDA Panel Says

Mar 31 2022

Radicava US Approval Boost To Mitsubishi As Sales Decline

May 08 2017

Therachon Moves 'Academic Prototype' Towards Clinic

May 05 2017

Related Companies

Mitsubishi Tanabe Pharma Corporation

Amylyx Pharmaceuticals, Inc.

Sanofi

AstraZeneca PLC

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Additional Topics

Approvals Business Strategies Commercial Neurology BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window